Table 3.
Effect of Etpost (2 μg/ml) against the RISK/SAFE kinase inhibitors on arrhythmia score, VT, and VF incidence during the reperfusion phase of the IR model
| Arrhythmia score |
VT incidence (%) |
VF incidence (%) |
|
|---|---|---|---|
| IR (Con.)@ | 3.23 ± 0.85 | 69.23 | 30.77 |
| IPOST (Con.) | 2.30 ± 0.75* | 50.00* | 10.00* |
| Etpost (2 μg/ml) | 4.33 ± 0.93* | 100.0* | 00.00* |
| Etpost (2 μg/ml) + Wort | 6.50 ± 0.83*,# | 100.0* | 66.67*,# |
| Etpost (2 μg/ml) + PD | 5.67 ± 0.34*,# | 66.67# | 100.0*,# |
| Etpost (2 μg/ml) + AG | 6.25 ± 0.75*,# | 50.0*,# | 100.0*,# |
| Etpost (2 μg/ml) + HD | 2.20 ± 0.17*,# | 100.0* | 00.000* |
| IPOST + Wort | 7.00 ± 0.00*,& | 100.0*,& | 100.0*,& |
| IPOST + PD | 7.00 ± 1.17*,& | 100.0*,& | 100.0*,& |
| IPOST + AG | 5.75 ± 1.25*,& | 50.00* | 50.00*,& |
| IPOST + HD | 3.00 ± 0.05& | 33.33*,& | 33.33& |
IR ischemic reperfusion, VT ventricular tachycardia, VF ventricular fibrillation, Etpost Ethyl acetate fraction of Potentilla reptans root in postconditioning, Wort Wortmanin (PI3K/Akt inhibitor), PD PD98059 (ERK inhibitor), AG AG490 a JAK/STAT3 inhibitor, HD 5HD a mitoKATP channel blocker. The scale range of arrhythmia score is 0–7. Data are presented as mean ± SEM. *P < 0.05 vs. IR; & P < 0.05 vs. IPOST; # P < 0.05 vs. Etpost (2 μg/ml). @: [7]